Sub	estitute for form 1449/PTO			Complete if Known	
				Application Number	10/551,643-Conf. #5446
11	VEORMATION	I DI	SCLOSURE	Filing Date	July 24, 2006
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Giovanni Monteleone
				Art Unit	1645
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	GIU-001

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear	
	A1*	US-5,654,004	08-05-1997	Okayama et al.		
	A2*	US-5,783,566	07-21-1998	Mislick		
	A3*	US-5,929,226	07-27-1999	Padmapriya et al.		
	A4*	US-6,096,722	08-01-2000	Bennett et al.		
	A5*	US-6,159,697	12-12-2000	Monia et al.		
	A6*	US-6,200,602	03-13-2001	Watts et al.		
	A7*	US-6,251,628	06-26-2001	Nakao et al.		
	A8*	US-6,455,689	09-24-2002	Schlingensiepen et al.		
	A9*	US-6,479,465	11-12-2002	Strober et al.		
	A10*	US-6,605,443	08-12-2003	Nakao et al.		
	A11*	US-6,794,367	09-21-2004	Tanida et al.		
	A12*	US-6,884,787	04-26-2005	Monia et al.		
	A13*	US-6,943,241	09-13-2005	Isogai et al.		
	A14*	US-20020177568	11-28-2002	Stinchcomb et al.		
	A15*	US-20050119203	06-02-2005	Steinbrecher et al.		
	A16*	US-20070042985	02-22-2007	Monteleone		

	FOREIGN PATENT DOCUMENTS									
	Cite No.1	Foreign Patent Document Country Code ⁵ -Number ⁶ -Kind Code ⁶ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear					
E	B1	WO-08/014400	01-31-2008	Genizon Biosciences Inc et al.		4				
E	B2	WO-99/050296	10-07-1999	Eli Lilly and Company		4				

"EXAMINED Initial Indexence considered, whether or not cluster is a conformance with MIFED 900. Date line through cluster in not in conformance and not considered include copy of this form with new communications to applicant." CTER No. These applications with less make with his region activate his new to the CIA. Date as a conformance of a model of the conformance of the

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	er Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	C1	Agrawal, S., et al., "Antisense Therapeutics: Is it as Simple as Complementary Base Recognition?", Molecular Medicine Today, February 2000 (Vol. 6), pps. 72-81.	Г				
	C2	Arsura, M., et al., "TGFβ1 Inhibits NF-κB/Rel Activity Inducing Apoptosis of B Cells: Transcriptional Activation of IκΒά, Immunity, Vol. 5, 31-40, July, 1996.					
	СЗ	Boirivant, M., et al., "Lamina Propria T Cells in Crohn's Disease and other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis," Gastroenterology, 1999: 115: 557-565.					
	C4	Boirivant, M., et al., "Oral Administration of Recombinant Cholera Toxin Subunit B Inhibits IL-					

Sub	estitute for form 1449/PTO			Complete if Known	
				Application Number	10/551,643-Conf. #5446
11	VIFORMATION	I DI	SCLOSURE	Filing Date	July 24, 2006
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Giovanni Monteleone
				Art Unit	1645
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	GIU-001

12-Mediated Murine Experimental (Trintrobenzene Sulfonic Acid) Colitis, "The Journal of Immunology, 2001. C5 Boirivant, M., et al., "Oxazolone Colitis: A Murine Model of T Helper Cell Type 2 Colltis Treatable with Antibodies to Interfeukin 4," The Journal of Experimental Medicine, Vol. 188, No. 10, November 16, 1998, 1929-1939. C6 Chits, M., et al., "Immune Dysregularation in TGF-β1-Deficient Mice," The Journal of Immunology, 1994. C7 Ficothi, C., "TGF-βY-Smad Signaling Defects in Inflammatory Bowel Disease: Mechanisms and Possible Novel Therapies for Chronic Inflammation," The Journal of Clinical Investigation, Vol. 198, No. 4, August 2001. C8 Gorelik, L. et al., "Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease," Immunity, Vol. 12, 171-181, February, 2000. Gorelik, L., et al., "Transforming Growth Factor-β in T-Cell Biology," Nature Reviews/Immunology, Vol. 2, January 2002. C1 Gueriavais, T., et al., "Use of Mald-TGF Mass Spectrometry to Monitor Solid-Phase Synthesis of Coliponucleoidose," Anal Biosnal Chem (2002) 374: 57-63. C1 Hahm, K. B., et al., "Loss of Transforming Growth Factor-β bisgnalling in the Intestine Contributes to Tissue Injury in Inflammatory Bowel Disease," Gut 2001;49: 190-198. C12 Han, Seung H., et al., "Transforming Growth Factor-Bet 1 (TGF-β1) Promotes L-2 mRNA Expression Through the Up-regulation of Nr-κ5, AP-1 and Nr-AT in EL4 Cells," The Journal of Pharmacology and Experimenting Thraspeutics, Vol. 287, No. 3, 1998 C13 Hayashi, H., et al., "The MAD-related Protein Smad? Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling from Cell Membrane to Nucleus Through SMAD Proteins," Nature, Vol. 399, 4 December 1997. C15 Lawrance, Ian Craig, et al., "Tif-Fβ Signaling from Cell Membrane to Nucleus Through SMAD Proteins," Nature, Vol. 399, 4 December 1997. C16 Lawrance, Ian Craig, et al., "Tif-Fβ Signaling from Cell Membrane to Nucleus Through SMAD Proteins," Nature, Vol. 399, 4 December 1997. C1			
Treatable with Antibodies to Interleukin 4," The Journal of Experimental Medicine, Vol. 188, No. 10, November 16, 1998, 1929-1939. C6 Christ, M., et al., "Immune Dysregularation in TGF-β1-Deficient Mice," The Journal of Immunology, 1994. C7 Fiocchi, C., "TGF-β/Smad Signaling Defects in Inflammatory Bowel Disease: Mechanisms and Possible Novel Therapies for Chronic Inflammation," The Journal of Clinical Investigation, Vol. 108, No. 4, August 2001. C8 Gerelik, L. et al., "Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmuno Disease," Immunity, Vol. 12, 171-181, February, 2000. Gorelik, L., et al., "Tansforming Growth Factor-β in T-Cell Biology," Nature Reviewel/Immunology, Vol. 2, January 2002. C10 Gueriavais, T., et al., "Use of Madd-TOF Mass Spectrometry to Monitor Solid-Phase Synthesis of Oligonucleotides," Anal Biosand Chem (2002) 374: 57-68. C11 Hahm, K. B., et al., "Loss of Transforming Growth Factor Signalling in the Intestine Contributes to Tissue Injury in Inflammatory Bowel Disease," Gut 2001;39: 190-198. C12 Han, Soung H., et al., "Transforming Growth Factor-Betta I (TGF-β1) Promotes IL-2 mRNA Expression Through the Up-regulation of Ni-rs. A. PA-1 and NF-AT in ELA Cells," The Journal of Pharmacology and Experimental Therapeutics, Vol. 287, No. 3. 1998. C13 Hayashi, H., et al., "The MAD-related Protein Smad? Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling," Cell, Vol. 89, 1165-1173, June 27, 1997. C15 Lawrance, lan Craig, et al., "Inflammation Louden Cell Membrane to Nucleus Through SMAD Proteins," Nature, Vol. 390, 4 December 1997. C15 Lawrance, lan Craig, et al., "Inflammation Louden Intestinal Fibrosis Down-Regulated by Antisense NF-38. "Gastroenterloopy 2003:125:1750-1761. C16 Lawrance, lan Cr., et al., "25 - Ciliganden/tale: Artisense Chimeras-Synthesis and Properties," Bioconjugate Chem. 1993, 4. 467-472. C18 Ludviksson, B.R., et al., "TGF-β Production Regulates the Development of the 2, 4, 6-Trinkropheno			П
Immunology, 1994.	C5	Treatable with Antibodies to Interleukin 4," The Journal of Experimental Medicine, Vol. 188, No. 10, November 16, 1998, 1929-1939.	
Possible Novel Therapies for Chronic Inflammation, "The Journal of Clinical Investigation, Vol. 108, No. 4, August 2001. C8 Gorellik, L. et al., "Abrogation of TGFβ Signaling in T Cell Bloody," Nature Reviews Inflammation and Audinmune Disease, "Immunity, Vol. 12, 171-181, February, 2000. C9 Gorellik, L. et al., "Transforming Growth Factor-β in T-Cell Biology," Nature Reviews/Immunology, Vol. 2, January 2002. C10 Guerlavais, T., et al., "Use of Meldi-TGF Meas Spectrometry to Monitor Solid-Phase Synthesis of Oliginuruleoidies." Anal Biolana Chem 2002 J 347: 57-63. C11 Hahm, K. B., et al., "Loss of Transforming Growth Factor β Signalling in the Intestine Contributes to Tissue Injury in Inflammatory Bowed Disease," Gut 2001:49: 199-198. C12 Hahn, Saung H., et al., "Transforming Growth Factor Signalling in the Intestine Properties of Progression Through the Up-registation of NF-36, AP-1 and NF-47 in El-4 Cells," The Journal of Pharmacology and Experimental Therapeutics, Vol. 287, No. 3. 1998. C13 Hayashi, H., et al., "The MAD-related Propeutics Syndry Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signalling," Cell, Vol. 59, 1165-1173, June 27, 1997. C14 Heldin, Carl Henrik, et al., "TGFβ Signalling from Cell Membrane to Nucleus Through SMAD Proteins," Nature, Vol. 390, 4 December 1997. C15 Lawrance, Ian Craig, et al., "Inflammation Location, But Not Type, Determines the Increase in TGFβ and Inflammation and Collagen Deposition in IBD Intestine," Inflammatory Bowel Diseases, Vol. 7, No. I, February 2001. C16 Lawrance, Ian Craig, et al., "Britammation Location, But Not Type, Determines the Increase in TGFβ and Inflammation Collagen Deposition in IBD Intestine," Inflammation Incl. 2-Deficient Mice, "The Juna of University Molecular Properties," Bioconipusate Chem. 1993, 4, 467-472. C16 Lawrance, Ian C., et al., "A Mirhm Model of Chronic Inflammation-Induced Intestinal Fibrosis Down-Regulated by Antisense Nimers Model of Chronic Inflammation in IL-2-Deficient Mice," The Juna of In	C6		
Differentiation and Autoimmune Disease, Immunity, Vol. 12, 171-181, February, 2000. C9 Grafilk, L., et al., "Transforming Growth Factor-β in T-Cell Biology," Nature Reviews/Immunology, Vol. 2, January 2000. C10 Guerlavia, T., et al., "Use of Malci-TOF Mass Spectrometry to Monitor Solid-Phase Synthesis of Oligonucleoides." Anal Biocanal Chem (2002) 374: 57-63. C11 Hahm, K. B., et al., "Use of Transforming Growth Factor β Signalling in the Intestine Contributes to Tissue Injury in Inflammatory Bowed Disease," Gut 2001;49: 190-198. C12 Han, Seung H., et al., "Transforming Growth Factor-Bet at (TGF-β1) Promotes IL-2 mRNA Expression Through the Up-regulation of NF-st, AP-1 and NF-AT in EL4 Cells," The Journal of Pharmacology and Experimental Therapeutics, Vol. 287, No. 3. 1998. C13 Hayashi, H., et al., "The MAD-related Protein Smart? Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling," Cell, Vol. 89, 1165-1173, June 27, 1997. C14 Heldin, Carl Henrik, et al., "TGF-β Signalling from Cell Membrane to Nucleus Through SMAD Proteins," Nature, Vol. 390, 4 December 1997. C15 Lawrance, Ian Craig, et al., "Intermation-Location, But Not Type, Determines the Increase in TGF-β1 and IGF-1 Expression and Collagen Deposition in IBD Intestine," Inflammatory Bowel Diseases, Vol. 7, No. 1, February 2001. C16 Lawrance, Ian C., et al., "A Murine Model of Chronic Inflammation-Induced Intestinal Fibrosis Down-Regulated by Antisense Nr88." Gastroenterloogy 2003:125:1750-1761. C17 Lesiak, Krystyna, et al., "25. "C-Digoadenytate: Antisense Chimeras-Synthesis and Proporties," Biocologypato Cham. 1993, 4, 467-472. C18 Ludvikeson, B.R., et al., "TGF-β Production Regulates the Development of the 2.4,6-Trintrophone Crollogypato Cham. 1993, 4, 467-472. C19 Maggi, A., Biotecnologie Tarmacologiche, 1998, Cap. 8: 125-131. √ Manger, A., Biotecnologie Tarmacologiche, 1998, Cap. 8: 125-131. √ Manger, A., Biotecnologie Tarmacologiche, 1998, Cap. 8: 125-131. √ Manger, A., Biotecnologie Tarmacologiche, 1998	C7	Possible Novel Therapies for Chronic Inflammation," The Journal of Clinical Investigation, Vol.	
Reviews/Immunology, Vol. 2, January 2002. C10 Querlavais, T., et al., "Use of Mald-ToF Mass Spectrometry to Monitor Solid-Phase Synthesis of Oligonucleotides." Anal Bioanal Chem (2002) 374: 57-53. C11 Hahm, K. B., et al., "Loss of Transforming Growth Factor β Signalling in the Intestine Contributes to Tissue Injury in Inflammatory Bowel Disease," Cut 2001;49: 190-198. C12 Han, Seung H., et al., "Transforming Growth Factor-Beta I (TGF-βI) Prototes IL-2 mRNA Expression Through the Up-regulation of NF-85, AP-1 and NF-AT in EL4 Cells," The Journal of Pharmacology and Experimental Therapeutics, Vol. 287, No. 3, 1998. C13 Hayashi, H., et al., "The MAD-Testael Protein Smard? Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signalling from Cell Membrane to Nucleus Through SMAD Proteins," Nature, Vol. 390, 4 December 1997. C15 Lawrance, Ian Craig, et al., "Inflammation Location, But Not Type, Determines the Increase in TGF-β1 and IGF-1 Expression and Collagen Deposition in IBD Intestine," Inflammatory Bowel Diseases, Vol. 7, No. 1, February 2001. C16 Lawrance, Ian C., et al., "A Murine Model of Chronic Inflammation-Uncude Intestinal Fibrosis Down-Regulated by Antisense NF-SB." Gastroenterology 2003;125:1750-1761. C17 Lesiak, Krystyna, et al., "25. "Gligoadenylate: Antisense Chimeras-Synthesis and Proporties," Bioconjugato Chem. 1993, 4, 467-472. C18 Ludviksson, B.R., et al., "TGF-β Production Regulates the Development of the 2, 4,6-Trinitrophenio-Conjugato Keryhold Limpet Hemocraynin-Induced Cotonic Inflammation in IL-2-Deficient Mice," The Journal of Immunology, 1997. C19 Maggi, A., Biotecnologie Farmacologiche, 1998, Caps. 8: 125-131. Morteloone, G., et al., "Blocking Smard Restores TGF-β1 Signaling in Chronic Inflammatory Bowel Disease," Organic Letters 2000, Vol. 2, No. 13, p. 1619-1822. C20 Morteloone, G., et al., "Blocking Smard Restores TGF-β1 Signaling in Chronic Inflammatory Bowel Disease," In Junnal of Clinical Investigation, August 2001, vol. 106, No. 4, p. 601-600. C22 N	C8		
of Oligonucleotides," Anal Bioanal Chem (2002) 374: 57-83. C11 Hahm, K. B., et al., "Loss of Transforming Growth Factor β Signalling in the Intestine Contributes to Tissue Injury in Inflammatory Bowel Disease," Gut 2001;49: 190-198. C12 Han, Seung H., et al., "Transforming Growth Factor Beta 1 (TGF-β1) Promotes IL-2 mRNA Expression Through the Up-regulation of NF-κβ, AP-1 and NF-AT in EL4 Cells," The Journal of Pharmacology and Experimental Threapeutics, Vol. 287, No. 3. 1998 C13 Hayashi, H., et al., "The IAD-Tested Protein Smar? Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signalling," Cell, Vol. 89, 1165-1173, June 27, 1997. C14 Heldin, Carl Henrik, et al., "TGFβ Signalling from Cell Membrane to Nucleus Through SMAD Proteins," Nature, Vol. 390, 4 December 1997. C15 Lawrance, Ian Craig, et al., "Inflammation Location, But Not Type, Determines the Increase in TGFβ and IGF-1 Expression and Collagen Deposition in IBD Intestine," Inflammatory Bowel Diseases, Vol. 7, No. 1, February 2001. C16 Lawrance, Ian C., et al., "A Murine Model of Chronic Inflammation-Induced Intestinal Fibrosis Down-Regulated by Antisense N-Rs." Gastroenterology 2003;125:1750-1761. C17 Lesiak, Krystyna, et al., "2:5-Ciligoadenylate: Antisense Chimeras-Synthesis and Proporties," Bioconipusate Chem. 1993, 4, 467-476. C18 Ludviksson, B.R., et al., "TGF-β Production Regulates the Development of the 2, 4,6-Trinitrophenio-Conjugated Keyhold Limpel Hemocraynin-Induced Cotonic Inflammation in IL-2-Deficient Mice," The Journal of Immunology, 1997. C19 Maggi, A., Biotecnologie Farmacologiche, 1998, Cap. 8: 125-131. C20 Marie, Martin A., et al., "Synthesis of Chimeric Ciligonucleotides Containing Phosphodester, Phosphoromitote, and Phosphoramidate Linkages," Organic Letters 2000, Vol. 2, No. 13, p. 1819-1822. C21 Monteloone, et al., "Blocking Smad7 Restores TGF-β1 Signaling in Chronic Inflammatory Bowel Disease," The Journal of Clinical Investigation, August 2001, vol. 108, No. 4, p. 601-600. C22 Neurath, M., e	C9	Reviews/Immunology, Vol. 2, January 2002.	
Contributes to Tissue Injury in Inflammatory Bowel Disease, "Gut 2001;49: 190-198. C12 Alan, Saung H., et al., "Transforming Growth Factor Set at 1(Tef-β1) Promotes IL-2 mRNA Expression Through the Up-regulation of NF-158, AP-1 and NF-AT in EL4 Cells," The Journal of Pharmacology and Experimental Therapeutics, Vol. 287, No. 3. 1998 C13 Hayashi, H., et al., "The MAD-related Protein Smad? Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling," Cell, Vol. 89, 1165-1173, June 27, 1997. C14 Heldin, Carl Henrik, et al., "TGFβ Signaling from Cell Membrane to Nucleus Through SMAD Proteins," Nature, Vol. 390, 4 December 1997. C15 Lawrance, Ian Craig, et al., "Inflammation Location, But Not Type, Determines the Increase in TGF-β1 and IGF-1 Expression and Collagen Deposition in IBD Intestine," Inflammatory Bowel Diseases, Vol. 7, No. 1, February 2001. C16 Lawrance, Ian C., et al., "A Murine Model of Chronic Inflammation-Induced Intestinal Fibrosis Down-Regulated by Antisense NF-8B, "Gastroenterology 2003;125:1750-1761. C17 Leslak, Krystyna, et al., "2:5-Ciligoadenylate: Antisense Chimeras-Synthesis and Properties, Bioconjugate Chem. 1993, 4, 467-472. C18 Ludvikson, B.R., et al., "TGF-β Production Regulates the Development of the 2, 4.6-Trinitrophenio-Conjugate Ckernylol Limpel Hemocryanin-Induced Colonic Inflammation in IL-2-Deficient Mice," The Journal of Immunology, 1997. C19 Magi, A., Biloteonologia Famacopigiche, 1998, Cap. 8: 125-131. C20 Maler, Martin A., et al., "Synthesis of Chimeric Oligonucleotides Containing Phosphodester, Phosphoromitote, and Phosphoramidate Linkages," Organic Letters 2000, Vol. 2, No. 13, p. 1819-1822. C21 Monteloone, G., et al., "Blocking Smad? Restores TGF-β1 Signaling in Chronic Inflammatory Bowel Disease," The Journal of Clinical Investigation, August 2001, vol. 108, No. 4, p. 601-600. C22 Neurath, M.F., et al., "Experimental Granulomatous Colitis in Mice is Abrogated by Induction of TGF-β-Medicated Oral Tolerance," J. Exp. Med., Vol. 18		of Oligonucleotides," Anal Bioanal Chem (2002) 374: 57-63.	
Expression Through the Up-regulation of NF-x8, AP-1 and NF-AT in EL4 Cells," The Journal of Pharmacology and Experimental Therapeulice, Vol. 287, No. 3. 1988 C13 Hayash, H., et al., "The MAD-related Protein Smad? Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling," Cell, Vol. 99, 1165-1173, June 27, 1997. C14 Heldin, Carl Henrik, et al., "TGFβ Signaling mor Cell Membrane to Nucleus Through SMAD Proteins," Nature, Vol. 390, 4 December 1997. C15 Lawrance, lan Craig, et al., "Inflammation Location, But Not Type, Determines the Increase in TGF-β1 and IGF-1 Expression and Collagen Deposition in IBD Intestine," Inflammatory Bowel Diseases, Vol. 7, No. 1, February 2001. C16 Lawrance, lan C., et al., "A Murine Model of Chronic Inflammation-Induced Intestinal Fibrosis Down-Regulated by Antissense Nrs88," Gastroenterology 2003;125:1750-1761. C17 Lesiak, Krystyna, et al., "25." —Oligoadenylate: Antisense Chimeras—Synthetis and Properties, Bioconjugate Chem. 1998, 4, 467-472. C18 Ludviksson, B.R., et al., "TGF-β Production Regulates the Development of the 2.4.6-Trinitrophenol-Conjugated Keyhold Limpel Hemocryanin-Induced Colonic Inflammation in IL-2-Deficient Mice," The Journal of Immunology, 1997. C19 Magic, A. Biotenchologie Farmacopiquies, 1998, Cap. 8: 125-131. C20 Maier, Martin A., et al., "Synthesis of Chimeric Oligonucletice Containing Phosphodiseter, Phosphorotholote, and Clinical Investigation, August 2001, vol. 108, No. 4, p. 601-809. C21 Monteloone, G., et al., "Blocking Smad? Restores TGF-β1 Signaling in Chronic Inflammatory Bowed Disease," The Journal of Clinical Investigation, August 2001, vol. 108, No. 4, p. 601-809. C22 Neurath, M.F., et al., "Experimental Granulomatous Colitis in Mice is Abrogated by Induction of TGF-β-Medicated Oral Tolerance," J. Exp. Med., Vol. 183, June 1996, p. 2605-2616. C23 Neurath, M., et al., "TMSE-Collis," Intern. Rev. Immunol., Vol. 19, p. 51-62. 2000. C24 Podolsky, D.K., "Inflammatory Bowel Disease," N. Engl. J. Med., Vol. 347, No.		Contributes to Tissue Injury in Inflammatory Bowel Disease," Gut 2001;49: 190-198.	
Eunctions as an Antagonist of TGFβ Signalling, "Cell, Vol. 89, 1165-1173, June 27, 1997. C14 Heldin, Carl Henki, et al., "TGF4 Signalling from Cell Membrane to Nucleus Through SMAD Proteins," Nature, Vol. 390, 4 December 1997. C15 Lawrance, Ian Craig, et al., "Inflammation Location, But Not Type, Determines the Increase in TGF-β1 and IGF-1 Expression and Collegen Deposition in IBD Intestine," Inflammatory Bowel Diseased, Vol. 7, No. 1, Patruary 201. C16 Lawrance, Ian Craig, et al., "Enturuery 201. C17 Lawrance, Ian Craig, et al., "A Murine Model of Chronic Inflammation-Induced Intestinal Fibrosis Down-Regulated by Antisenses NF-x8," Gastroenterology 2003:125/1750-1761. C17 Laurance, Ian Craig, et al., "C5 Poliogoderylate: Antisenses Chimera—Symthesis and Properties," Bioconjugate Chem. 1993, 4, 467-472. C18 Ludviksson, B.R., et al., "C5 Production Regulates the Development of the 2,4,6-Trinitrophenol-Conjugated Keyhold Limpet Hemocyamin-Induced Colonic Inflammation in IL-2-Deficient Mice," The Journal of Immunology, 1997. C19 Maggi, A., Biotecnologie Farmacologicine, 1998, Cap. 8: 125-131. C20 Maier, Martin A., et al., "Synthesis of Chimeric Ciliponucleotides Containing Phosphodester, Phosphororthioate, and Phosphoramidate Linkages," Organic Letters 2000, Vol. 2, No. 13, p. 1819-1822. C21 Monteleone, G., et al., "Biocking Smad7 Restores TGF-β1 Signaling in Chronic Inflammatory Bowed Disease," The Journal of Indical Investigation, August 2001, vol. 108, No. 4, p. 501-509. C22 Neurath, M.F., et al., "Experimental Granulomatous Colitis in Mice is Abrogated by Induction of TGF-β1-Medicated Oral Tolerance," J. Exp. Med., Vol. 183, June 1996, p. 2005-2616. C23 Neurath, M., et al., "TNBS-Collits," Intern. Rev. Immunol., Vol. 19, p. 51-62. 2000 C24 Poddisky, D.K., "Inflammatory Bowel Disease," N. Engl. J. Med., Vol. 347, No. 6, August 8, 2002.	C12	Expression Through the Up-regulation of NF-κB, AP-1 and NF-AT in EL4 Cells," The Journal	
Proteins, "Nature, Vol. 380, 4 December 1997. C15 Lawrance, Ian Craig, et al, "Inflammation Location, But Not Type, Determines the Increase in TGF-β1 and IGF-1 Expression and Collagen Deposition in IBD Intestine," Inflammatory Bowel Diseases, Vol. 7, No. 1, February 2001. C16 Lawrance, Ian C., et al., "A Murine Model of Chronic Inflammation-Induced Intestinal Fibrosis Down-Requitated by Antisense NF-83: Castroenterology 2003:126:1750-1761. C17 Lesiak, Krystyna, et al., "2,5"-Oligoadenylate: Antisense Chimeras-Synthesis and Properties." Bioconlugate Chem. 1993. 4, 467-472. C18 Lutviksson, B.R., et al., "75"-Production Regulates the Development of the 2,4,6-17tintrophenol-Conjugated Keyhold Limpet Hemocyamin-Induced Colonic Inflammation in IL-2-Deficient Mice," The Journal of Immunology, 1997. C19 Maggi, A., Biotecnologie Farmacologiche, 1998, Cap. 8: 125-131. √ C20 Maier, Martin A., et al., "Synthesis of Chimeric Ciliponucleotides Containing Phosphodiester, Phosphororthicate, and Phosphoramidate Linkages," Organic Letters 2000, Vol. 2, No. 13, p. 1619-1822. C21 Monteloone, G., et al., "Biocking Smad7 Restores TGF-β1 Signaling in Chronic Inflammatory Bowel Disease," The Journal of Clinical Investigation, August 2001, vol. 108, No. 4, p. 601-609. C22 Neurath, M.F., et al., "Experimental Granulomatous Colitis in Mice is Abrogated by Induction of TGF-β1-Medicated Oral Tolerance," J. Exp. Med., Vol. 183, June 1996, p. 2005-2616. C23 Neurath, M.F., et al., "TNBS-Collis", intern. Rev. Immunol., Vol. 19, p. 51-62 Z000, p. 417-425. "Inflammatory Bowel Disease," N. Engl. J. Med., Vol. 34, No. 6, August 8, 2002, p. 417-425.	C13		
TGF-β1 and IGF-1 Expression and Collagen Deposition in IBD Intestine," Inflammatory Bowel Diseases, Vol. 7, No. 1, February 2001. C16 Lawrance, Ian C., et al., "A Murine Model of Chronic Inflammation-Induced Intestinal Fibrosis Down-Requitated by Antisense Nr-8B. "Gastroentorlogy 2003:125:1750-1761. C17 Lesiak, Krystyra, et al., "2:6 - Oligoadenylate: Antisenses Chimeras – Synthesis and Proporties, Bioconjugate Chem. 1993. 4, 467-472. C18 Ludviksson, B.R., et al., "TGF-β Production Regulates the Development of the 2.4,6-Traitrophenol Conjugate Chem. 1993. 4, 467-472. C19 Maggi, A., Biotecnologie Farmacologiche, 1999. Cap. 8: 125-131. C20 Maggi, A., Biotecnologie Farmacologiche, 1999. Cap. 8: 125-131. C21 Maggi, A., Biotecnologie Farmacologiche, 1998, Cap. 8: 125-131. Maggi, A., Biotecnologie Farmacologiche, 1998, Cap. 8: 125-131. C22 Montoloone, G., et al., "Blocking Smad7 Restores TGF-β1 Signaling in Chronic Inflammatory Bowed Disease," The Journal of Clinical Investigation, August 2001, vol. 108, No. 4, p. 601-1099. C22 Neurath, M.F., et al., "Experimental Granulomatous Colitis in Mice is Abrogated by Induction of TGF-β1-Medicated Oral Tolerance," J. Exp. Med., Vol. 183, June 1996, p. 2005-2616. C23 Neurath, M.F., et al., "TNBS-Collist," intern. Rev. Immunon, Vol. 19, p. 51-62. 200 O. C24 Podolsky, D.K., "Inflammatory Bowel Disease," N. Engl. J. Med., Vol. 34, No. 6, August 8, 2002, p. 417-425.	C14		
Down-Regulated by Antisense NF-kB." Gastroenterology 2003;125:1750-1761. C19 Lesiak, Krystyna, et al., 72;6-Cligoadenylate: Antisense Chimeras-Synthesis and Properties. Bioconipuste Chem. 1993, 4, 467-472. C18 Ludvikson, B.R., et al., "TGF-β Production Regulates the Development of the 2,4.6-Trinitrophenol-Conjugated Keyhold Limpet Hemocyantin-Induced Colonic Inflammation in IL-2-Deficient Mice," The Journal of Immunology, 1997. C19 Magig, A., Bilotecnologie Farmacoplogiche, 1998, Cap. 8: 125-131. C20 Maler, Martin A., et al., "Synthesis of Chimeric Oligonucleotides Containing Phosphodiester, Phosphorothioside, and Phosphoramidate Linkages," Organic Letters 2000, Vol. 2, No. 13, p. 1819-1822. C21 Monteleone, G., et al., "Blocking Smad7 Restores TGF-β1 Signaling in Chronic Inflammatory Bowd Disease," The Journal of Clinical Investigation, August 2001, vol. 108, No. 4, p. 601-699. C22 Neurath, M.F., et al., "Experimental Granulomatous Colitis in Mice is Abrogated by Induction of TGF-β-Medicated Oral Tolerance," J. Exp., Med., Vol. 183, June 1996, p. 2605-2616. C23 Neurath, M. et al., "TMBS-Collis," intern. Rev. Immunol., Vol. 189, p. 51-62. 2000. C24 Podolsky, D.K., "Inflammatory Bowel Disease," N. Engl. J. Med., Vol. 347, No. 6, August 8, 2002, p. 417-428.	C15	TGF-β1 and IGF-1 Expression and Collagen Deposition in IBD Intestine," Inflammatory Bowel	
Properties,* Bioconjugate Chem. 1993, 4, 467-472. C18 Ludylkses n, B.R., et al., "TGF-β Production Regulates the Development of the 2.4.6-Trinitrophenol-Conjugated Keyhold Limpet Hemocyanin-Induced Colonic Inflammation in IL-2-Deficient Mice," The Journal of Immunology, 1997. C19 Magig, A. Biotecnologia Farmacologiche, 1998, Cap. 8: 125-131. C20 Maier, Martin A., et al., "Synthesis of Chimeric Oligonucleotides Containing Phosphodiester, Phosphorothioside, and Phosphoramidate Linkages," Organic Letters 2000, Vol. 2, № 13, p. 1819-1822. C21 Monteleone, G., et al., "Blocking Smad7 Restores TGF-β1 Signaling in Chronic Inflammatory Bowel Disease," The Journal of Clinical Investigation, August 2001, vol. 108, № 4, p. 601-609. C22 Neurath, M.F., et al., "Experimental Granufomatous Collitis in Mice is Abrogated by Induction of TGF-β-Medicated Oral Tolerance," J. Exp. Med., Vol. 183, June 1996, p. 2605-2616. C23 Neurath, M., et al., "TNBS-Collis," intern. Rev. Immunol., Vol. 189, p. 31-52, 2000. C24 Podolsky, D.K., "Inflammatory Bowel Disease," N. Engl. J. Med., Vol. 347, No. 6, August 8, 2002, p. 147-245.	C16		
Trinitrophenol-Conjugated Keyhold Limpet Hemocyanin-Induced Colonic Inflammation in IL-2-Deficient Mice, The Journal of Immunology, 1997. C19 Maggi, A., Biotecnologie Farmacolpgiche, 1998, Cap. 8: 125-131. C20 Maier, Martin A., et al., "Synthesis of Chimeric Cligonucleolides Containing Phosphodiester, Phosphorothioside, and Phosphormalidate Linkages," Organic Letters 2000, Vol. 2, No. 13, p. 1819-1822. C21 Monteleone, G., et al., "Blocking Smad7 Restores TGF-β1 Signaling in Chronic Inflammatory Bowel Disease," The Journal of Clinical Investigation, August 2001, vol. 108, No. 4, p. 601-609. C22 Neurath, M.F., et al., "Experimental Granulomatous Collitis in Mice is Abrogated by Induction of TGF-β-Medicated Oral Tolerance," J. Exp. Med., Vol. 183, June 1996, p. 2605-2616. C23 Neurath, M., et al., "TMBS-Collis," intern. Rev. Immunol., Vol. 189, p. 51-52, 2000 C24 Podolsky, D.K., "Inflammatory Bowel Disease," N. Engl. J. Med., Vol. 347, No. 6, August 8, 2002, p. 417-425.		Properties," Bioconjugate Chem. 1993, 4, 467-472.	
C20 Maier, Martin A., et al., "Synthesis of Chimeric Oligonucleotides Containing Phosphodiseter, Phosphorothole, and Phosphoralidate Linkages," Organic Letters 2000, Vol. 2, No. 13, p. 1819-1822. C21 Monteleone, G., et al., "Blocking Smad7 Restores TGF-β1 Signaling in Chronic Inflammatory Bowel Disease," The Journal of Clinical Investigation, August 2001, vol. 108, No. 4, p. 601-609. C22 Mourath, M.F., et al., "Experimental Granulomatous Colitis in Mice is Abrogated by Induction of TGF-β-Medicated Oral Tolerance," J. Exp. Med., Vol. 183, June 1996, p. 2605-2618. C23 Neurath, M., et al., "TMSS-Collis", Intern. Rev. Immunol., Vol. 19, p. 51-62. 2000 C24 Podolsky, D.K., "Inflammatory Bowel Disease," N. Engl. J. Med., Vol. 347, No. 6, August 8, 2002, p. 417-428.	C18	Trinitrophenol-Conjugated Keyhold Limpet Hemocyanin-Induced Colonic Inflammation in IL-2-	
Phosphorothioate, and Phosphoramidate Linkages, *Organic Letters 2000, Vol. 2, No. 13, p. 1819-1822. C21 Montoleone, G., et al., "Blocking Smad7 Restores TGF-β1 Signaling in Chronic Inflammatory Bowel Disease," The Journal of Clinical Investigation, August 2001, vol. 108, No. 4, p. 501-509. C22 Neurath, M.F., et al., "Experimental Granulomatous Colitis in Mice is Abrogated by Induction of TGF-β-Medicated Craft Tolerance," J. Exp. Med., Vol. 183, June 1996, p. 2605-2616. C23 Neurath, M., et al., "TNBS-Colitis," Intern. Rev. Immunol., Vol. 19, p. 51-62. 2000 C24 Podolsky, D.K., "Inflammatory Bowel Disease," N. Engl. J. Med., Vol. 347, No. 6, August 8, 2002, p. 417-426.	C19	Maggi, A., Biotecnologie Farmacolpgiche, 1998, Cap. 8: 125-131.	V
Bowel Disease,* The Journal of Clinical Investigation, August 2001, vol. 108, No. 4, p. 601- 609. C22 Neurath, M.F., et al., "Experimental Granulomatous Collitis in Mice is Abrogated by Induction of TGF-Jh-Medcated Oral Tolerance," J. Exp. Med., Vol. 183, June 1996, p. 2605-2616. C23 Neurath, M., et al., "TMBS-Collis," Intern. Rev. Immunol., Vol. 19, p. 51-62, 2000 C24 Podolsky, D.K., "Inflammatory Bowel Disease," N. Engl. J. Med., Vol. 347, No. 6, August 8, 2002, p. 417-426.	C20	Phosphorothioate, and Phosphoramidate Linkages," Organic Letters 2000, Vol. 2, No. 13, p.	
TGF-β-Medicated Oral Tolerance," J. Exp. Med., Vol. 183, June 1996, p. 2605-2616. C23 Neurath, M., et al., "TNBS-Collis," Intern. Rev. Immunol., Vol. 19, p. 51-62. 2000 C24 Podolsky, D.K., "Inflammatory Bowel Disease," N. Engl. J. Med., Vol. 347, No. 6, August 8, 2002, p. 417-429.	C21	Bowel Disease," The Journal of Clinical Investigation, August 2001, vol. 108, No. 4, p. 601-	
C24 Podolsky, D.K., "Inflammatory Bowel Disease," N. Engl. J. Med., Vol. 347, No. 6, August 8, 2002, p. 417-429.	C22		
2002, p. 417-429.	C23	Neurath, M., et al., "TNBS-Colitis," Intern. Rev. Immunol., Vol. 19, p. 51-62. 2000	
C25 Powrie, F., et al., "A Critical Role for Transforming Growth Factor-β but not Interleukin 4 in the	C24		
	C25	Powrie, F., et al., "A Critical Role for Transforming Growth Factor-8 but not Interleukin 4 in the	

Sub	stitute for form 1449/PTO			Complete if Known	
				Application Number	10/551,643-Conf. #5446
11	VEORMATION	1 DI	SCLOSURE	Filing Date	July 24, 2006
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Giovanni Monteleone
				Art Unit	1645
	(Use as many sh	eets a:	s necessary)	Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	GIU-001

	Supression of T Helper Type 1-Mediated Colitis by CD45RBlow CD4+ T Cells, "J. Exp. Med., Vol. 183, June 1996, p. 2669-2674.
C26	Ragas, J.A., "A Comparative Study on Methods of Optimal Sample Preparation for the Analysis of Oligonucleotides by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry," Analyst, 2000, 125, p. 575-581.
C27	Read, S., et al., "Induction of Inflammatory Bowel Disease in Immunodeficient Mice by Depletion of Regulatory T Cells," Current Protocols in Immunology (1999) 15.13.1-15.13.10.
C28	Sanborn, et al., "Biologic Therapy of Inflammatory Bowel Disease," Gastroenterology 2002:122:1592-1608.
C29	Sanghvi, Y.S., et al., "Antisense Oligodeoxynucleotides: Synthesis, Biophysical and Biological Evaluation of Oligodeoxynucleotides Containing Modified Pyrimidines," Nucleic Acids Research, 1993, Vol. 21, No. 14, 3197-3203.
C30	Seegers, D., et al., "Review Article: A Critical Approach to New Forms of Treatment of Crohn's Disease and Ulcerative Colitis," Aliment Pharmacol Ther 2002: 16(Suppl. 4): 53-58.
C31	Shull, M.M., et al., "Targeted Disruption of the Mouse Transforming Growth Factor-β1 Gene Results in Multifocal Inflammatory Disease," Nature, Vol. 359, 22 October 1992, p. 693-698.
C32	Wei, X, et al., "Synthesis and Characterization of Composite Nucleic Acids Containing 2",5" Oligin Development 6:247-256 (1996).
C33	Yang, X., "Targeted Disruption of SMAD3 Results in Impaired Mucosal Immunity and Diminished T Cell Responsiveness to TGF-β," The EMBO Journal, Vol. 18, No. 5, pp. 1280-1291, 1999.

Examiner Signature	/Kimberly Chong/	Date Considered	11/09/2009

^{*}EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.